1/95
関連するスライド
V20って何？ 肺がんカンファレンス前に 知っておきたい3つのこと
江口真澄
86414
145
Ⅳ期非小細胞肺がん 2nd Line以降化学療法
Antaa運営事務局
3586
24
いま改めて扁平上皮癌
キュート先生
8032
50
WCLC2023肺がんまとめ
Antaa運営事務局
6611
54
2024年米国臨床腫瘍学会（ASCO）肺がんまとめ
順天堂大学
98,362
224
概要
本スライドでは、2024年の米国臨床腫瘍学会（ASCO）で取り上げられた胸部腫瘍領域の重要演題（17演題）を周辺知識と併せて解説しています。発表された結果をまとめるだけでなく、現地でのディスカッション内容も含んでいるので、読むだけで最新情報にキャッチアップできます。
本スライドの対象者
研修医／専攻医／専門医
参考文献
スライド中に記載
投稿された先生へ質問や勉強になったポイントをコメントしてみましょう！
0 件のコメント
このスライドと同じ診療科のスライド
テキスト全文
ASCO 2024の概要とアジェンダ
#1.
My Best of ASCO 2024 @M_Torasawa
#2.
MARIPOSA #8504 @M_Torasawa PALOMA-3 NSCLC Oral (N = 43) Pickup #LBA8505 EGFR 1 HARMONi-A #8508 1 CHRYSALIS-2 n=2 MPM ADRIATIC #LBA5 n=4 #8001 CheckMate77T #LBA8007 AEGEAN #8011 #LBA8503 ROS1 Driver NSCLC n = 16 SCLC BEAT-SC CROWN ALK n=3 TRUST-1 #8520 CodeBreaK 101 KRAS NSCLC n=5 NSCLC n=6 CheckMate816 / Driver NSCLC n=5 #LBA8010 EVOKE-01 #LBA8500 #8516 #8512 KRYSTAL-12 HER2 #LBA8509 FGFR EGFR ALK Beamion LUNG-1 #8514 LAURA ADAURA #8005 #LBA4
#3.
Agenda 01 EGFR NSCLC 02 EGFR NSCLC 03 SCLC @M_Torasawa 04 NSCLC ( / )
EGFR NSCLCに関する最新の研究
#4.
Agenda 6 @M_Torasawa pickup 01 EGFR NSCLC ü LAURA III (#LBA4) ü ADAURA (#8005) ü MARIPOSA ü HARMONi-A ü PALOMA-3 (#8504) (#8508) (#LBA8505) Uncommon ü CHRYSALIS-2 (#8516) 02 EGFR NSCLC 03 SCLC 04 NSCLC ( / )
#5.
I III EGFR NSCLC EGFR NSCLC @M_Torasawa EGFR NSCLC IA1 2 IIA IIIA IA3 IB IV 2023 IIA UFT 2cm 1A 1A 2cm 2C 1A 3 1C 1B ( Pickup #LBA4 LAURA III EGFRm NSCLC 2023 EGGR 2B ) ASCO 2024 CRT Pickup ASCO 2024 #8005 ADAURA ADAURA MRD
#6.
EGFR NSCLC @M_Torasawa ± FLAURA 1A REVEL, JVCG 1A ICI + ICI ± + IMpower150, KEYNOTE-789, ORIENT-31, CheckMate722, ATTLAS 2A RELAY + + Dato-DXd, TROP2 ± TROPION-Lung05 MARIPOSA-2 2B ARCHER1050 KEYNOTE-010, CheckMate-057, OAK HER3-Dxd + + HERTHENA-Lung01 FLAURA2 + + MARIPOSA Pickup Pickup ASCO 2024 #8504 MARIPOSA EGFRm + MARIPOSA 2023 ( + NSCLC ド ASCO 2024 Pickup ASCO 2024 #8508 HARMONi-A #LBA8505 PALOMA-3 EGFR-TKI EGFR-TKI, ) EGFRm Non-sq NSCLC PD-1/VEGF 2023 vs. EGFRm NSCLC
EGFR変異に対する治療法の比較
#7.
Uncommon EGFR NSCLC Exon 20ins Exon18-21 Uncommon EGFR-TKI 2C [1] ORR PFS 10.7 71% PFS 9.4 [2] ORR 55% + PAPILLON + Pickup #8516 WU-KONG1 (abst#8513) ASCO 2024 CHRYSALIS-2 Uncommon EGFRm NSCLC 2023 2023 @M_Torasawa [1] Yang JCH, et al. Lancet Oncol. 2015;16(7):830-838.,[2] Okuma Y, et al. JAMA Oncol. 2024;10(1):43-51. Pickup
#8.
Pickup テ III EGFRm NSCLC CRT LAURA #LBA 4 (Plenary session) S. Ramalingam, et al. Lu Shun, Kato Terufumi, Dong Xiaorong, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 0(0). doi:10.1056/NEJMoa2402614 @M_Torasawa
#9.
Pickup テ LAURA N =143 III EGFRm NSCLC Ex19del/L858R PS 0-1 CRT ( IIIB IIIC 9 7 @M_Torasawa 80mg PFS (BICR) R 2:1 OS CRT N = 73 6 (IIIA vs IIIB/IIIC) / ) 8 (49 ) IIIA (35 ) (16 ) cCRT RT IMRT ( 8 12 48 CT, MRI) PFS (BICR PFS 13% PD 25% AE final OS ) f/u PFS 22.0 28% (n = 15) PD ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 Osi positive 7% PD 74% α maturity 60% f/u AE PFS 5.6 81% (n = 50) PD Osi
#10.
Pickup テ LAURA PFS (BICR) 60 @M_Torasawa 2 PFS 0.16, (95%CI 0.10 0.24) p < 0.001 48 65% OS 60 13% 48 36 24 12 0.81, (95%CI 0.42 1.56) p = 0.53 36 39.1 5.6 0 24 1 PFS 12 74% 54.0 0 22% Maturity 20% ( PFS HR EGFR <65 65 CRT Never L858R IIIA cCRT CR Ever Ex19del IIIIB/IIIC sCRT PR PFS ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 SD 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 60% )
ADAURA試験の結果と意義
#11.
Pickup テ LAURA @M_Torasawa 68% 22% -40 21% 48% -20 0 8% 29% 6% 29% 1% 7% 3% 7% 16% 37% 1% 1% ü ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 20 40 60 80 (%)
#12.
Pickup テ LAURA 29% 56% @M_Torasawa n = 63* 28 44% 12 19% 16 25% 15 24% 1 2% 0 0% 8 13% 21 33% 19 30% 5 8% 21 33% 2 3% EGFR-TKI 1/2G TKI 3G TKI - Osimertinib - Aumolertinib - Furmonertinib VEGF 78% 10% n = 66* 57 86% 7 11% 52 79% 51 77% 1 2% 1 2% 5 8% 11 17% 7 11% 1 2% 5 8% 2 3% * 8 ü ü RT beyond = 8.3 24 35% G3 ILD 8% G1/2, G5 1 13% 12% 48% G3 AE ILD 1% G1/2 G3 2% ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 5% 38% AE G1 G1/2
#13.
Pickup テ @M_Torasawa 10.9mo CRT 18.9mo Ami (SC) + Laz Cb + PEM Osi 6.1mo 4.2mo Ami (SC) + Laz Cb + PEM + Osi 23.7mo CRT 1 380 168,120 4.2mo Cb + PEM Ami + Laz G3 AE 6.1mo 25.5mo CRT 3 / 93,000 145 83,430 39.1mo 4 63 4 44,000 8.3mo Cb + PEM + Ami + Laz CRT Osi 6.3mo Cb + PEM + Ami CRT Osi PFS ( ) LAURA
#14.
Pickup テ LAURA Summary Discussion points EGFR 01 02 03 NSCLC PFS @M_Torasawa CRT 84% OS 20% MRD TKI PACIFIC . 80% (ADAURA . / PACIFIC-R EGFR subset ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 ( 40% ) )
MRDとEGFRm NSCLCの関連性
#15.
Pickup EGFRm IB-IIIA ADAURA NSCLC MRD #8005 (Oral abstract) T. John, et al. @M_Torasawa
#16.
Pickup デ ADAURA @M_Torasawa N = 339 IB-IIIA EGFRm NSCLC 3 R 24 1:1 Ex19del/L858R PS 0-1 MRD (IB / II / IIIA) (Ex19del / L858R) / ) 12, 24 ctDNA ASCO2024, abst #8005 , ctDNA 1 5 24 24 24 12, 24 12 3 Germline variant CHIP , Follow-up Adjuvant MRD WES 12, 24 5 1 N = 343 EGFR ( ctDNA 80mg ctDNA 52 , 52 24 5 MRD
#17.
Pickup デ ADAURA MRD @M_Torasawa N = 220 8% (n = 112) MRD ü Stage I 0% 92% ü Stage II 8% ü Stage III 13% MRD (17/18 MRD 2.2 5.6 1 MRD MRD (18/220 ) ( ) DFS 49% 80% 0% 4/5 8% MRD 17% 0/13 31% 75% 80% 2 MRD 66% 57% 1 ASCO2024, abst #8005 13% 5% 4.7 DFS MRD 7% (n = 108) (3 )
#18.
Pickup デ ADAURA MRD MRD/DFS MRD 01 02 03 Summary Discussion points DFS 4.7 MRD IMpower010 MRD MRD 62% MRD MRD 4/5 MRD MRD ASCO2024, abst #8005 / MRD @M_Torasawa
MARIPOSA試験の成果と分析
#19.
Pickup EGFRm NSCLC MARIPOSA ト + #8504 (Oral abstract) E. Felip, et al. @M_Torasawa
#20.
Pickup ト MARIPOSA @M_Torasawa Ami + N = 429 ( EGFR+ NSCLC PS 0 1 L858R, Ex19 del AMI 1050mg 1400mg 4 1 Laz 1 240mg R Osi ü ü ü OS ORR DoR PFS2 ) 1 80mg EGFR Ex19del / L858R / TP53 N = 216 ( ctDNA NGS Ex19del L858R ctDNA TP53mt (n = 293, 54%) TP53wt (n = 247, 46%) ASCO2024, abst #8504 PFS (Ami + Laz vs Osi) 2 N = 429 ( 2:2:1 ü ü 80kg ) Guardant360 CDx EGFRm ctDNA EGFRm ctDNA ) C3D1 Biodesix ddPCR ctDNA TP53 50% vs 30% C3D1 70% EGFR 100% 80% 60% 40% 20% 0% 85% 9
#21.
Pickup ト MARIPOSA PFS @M_Torasawa PFS ( ) HR 0.69, p = 0.010 41% HR 0.69, p = 0.005 16% HR 0.58, p = 0.017 HR 0.74, p = 0.004 54% 70% TP53mt HR 0.65, p = 0.003 TP53wt HR 0.75, p = 0.114 ctDNA+ HR 0.68, p = 0.002 ctDNA- HR 0.72, p = 0.132 HR 0.49, p = 0.015 15% HR 0.64, p = 0.004 0 5 10 Ami+Laz ASCO2024, abst #8504 15 Osi 20 25 30
#22.
Pickup ト MARIPOSA Summary + 02 FLAURA2 03 Molecular FLAURA2 PFS ASCO2024, abst #8504 @M_Torasawa PFS Front line 01 Discussion points 25.5 . MET .
HARMONi-A試験の結果と影響
#23.
Pickup EGFR-TKI ド EGFRm Non-sq NSCLC HARMONi-A #8508 (Oral abstract) L. Zhang, et al. HARMONi-A Study Investigators, Fang W, Zhao Y, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.10613 @M_Torasawa
#24.
Pickup ド HARMONi-A @M_Torasawa + CBDCA +PEM N = 161 EGFR+ NSCLC + PEM R EGFR 1:1 PS 0-1 EGFR-TKI ü ü + CBDCA + PEM N = 161 24 + PEM 3G TKI PFS (IRRC) AK112/SMT112 PD-1/VEGF VEGF PD-1 10 (J Immunother Cancer. 2023) OS ORR DoR TTR EGFR-TKI 3G 3 1/2G 3G 5 f/u 2 7.89 ASCO2024, abst #8508, Fang W, et al. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.10613, https://www.smmttx.com/wp-content/uploads/2023/12/Ivonescimab-Overview-HCPs-INVESTORS-MEDIA-12.7.23.pdf
#25.
Pickup ド HARMONi-A @M_Torasawa 6 PFS PFS 0.46, (95%CI 0.34 0.62) p < 0.0001 12 PFS EGFR 55% 10 <65 8 65 6 4 2 DCR OS 24 20 51% 35% 93% Ever Ex19del 33% 0 ORR L858R Other 4.8 7.1 Never 3G-TKI 83% 52%Maturity (f/u 0.80, (95%CI 0.59 1.08) 16 17.6 HR 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 ) G3 irAE 6% 3% G3 VEGF 3% 3% 12 8 4 0 17.1 14.5 ASCO2024, abst #8508, Fang W, et al. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.10613, https://www.smmttx.com/wp-content/uploads/2023/12/Ivonescimab-Overview-HCPs-INVESTORS-MEDIA-12.7.23.pdf
#26.
Pickup ド EGFRm NSCLC ICI PFS ( @M_Torasawa ) CBDCA+PTX+BEV+Atezo CBDCA+PTX+Atezo CBDCA+PTX+BEV IMpower150 71% 36% 42% 48% 35% 29% CBDCA+PTX (PEM) +BEV+Atezo IMpower151 CBDCA+PTX (PEM) CDDP+PEM+sintilimab IBI305 CDDP+PEM+sintilimab CDDP+PEM Orient-31 CBDCA+PTX+BEV+Atezo ATTLAS CBDCA+PEM+Nivo CBDCA+PEM CheckMate722 CBDCA+PEM+Pembro CBDCA+PEM KEYNOTE-789 CBDCA+PEM+Ivonescimab HARMONi-A 51% CBDCA+PEM 0 2 42% 70% CBDCA (CDDP)+PEM 4 Chemo+ICI+VEGFi 6 Chemo+ICI 8 Chemo ASCO2024, abst #8508, Fang W, et al. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.10613 10 12 PFS 31% 27% 29% 27% 35%
KRAS変異に対する新しい治療戦略
#27.
Pickup ド HARMONi-A Summary Discussion points EGFR-TKI 01 02 03 策 VEGF PD-L1 @M_Torasawa PFS VEGF+PD-1 ABCP OS MARIPOSA-2 PFS ICI MARIPOSA-2 [Ami + Chemo]: 6.3 , HARMONi-A: 7.1 ASCO2024, abst #8508, Fang W, et al. JAMA. Published online May 31, 2024. doi:10.1001/jama.2024.10613, https://www.smmttx.com/wp-content/uploads/2023/12/Ivonescimab-Overview-HCPs-INVESTORS-MEDIA-12.7.23.pdf
#28.
Pickup ナ EGFRm NSCLC vs. PALOMA-3 #LBA8505 (Oral abstract) LB. Neighl, et al. Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFRmutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. J Clin Oncol. Published online June 10, 2024:JCO2401001. @M_Torasawa
#29.
Pickup PALOMA-3 @M_Torasawa Ami ( EGFR+ NSCLC ・ R PS 0 1 L858R, Ex19 del )+ N = 206 4 1:1 Ami ( )+ N = 212 2 AUC ORR PFS ( DoR ) AMI ü ü EGFR ü ü / Osi / Ex19del / L858R 4 Ami 1600mg 2240mg 80kg 1 1050mg 1400mg 80kg Laz 1 240mg 2 OS 7.0 7 GMR 6 35% 2 C trough C2D1 C trough C4D1 C2 AUCD1-D15 1.15 (90 CI 1.04 1.26) 1.43 (90 CI 1.27 1.61) 1.03 (90 CI 0.98 1.09) ü ASCO2024, abst #LBA8505, Leighl NB, et al. J Clin Oncol. Published online June 10, 2024:JCO2401001.
#30.
Pickup PALOMA-3 @M_Torasawa PFS 100 Best reponse (%) 30 45 50 18 12 CR 32 10 PR 8 SD 4 6 2 PD 38 OS 20 IV SC IV Confirmed 27% (21 33) 27% (21 33) SC 4.3 SC IV 0.62, (95%CI 0.42 0.92) p = 0.017 ORR PFS, OS 6.1 0 NE 0 SC 0.84, (95%CI 0.64 1.10) p = 0.20 1 OS 12 10 8 ASCO2024, abst #LBA8505, Leighl NB, et al. J Clin Oncol. Published online June 10, 2024:JCO2401001. SC IV 65% 51% SC IV
CROWN試験の結果と臨床的意義
#31.
Pickup PALOMA-3 @M_Torasawa IRR VTE 66% 70 50 40 20 10 13% G1 2 15 G3 10 SC IV 0 IRR 70 26% 12% 9% G1 7% G2 G3 SC SC IV IV SC IV 65% 60 G1 50 40 ( Grade) ( Grade) G2 30 10 (42/39) 17% 14% 5 0 20 (164/171) (206/210) 20 60 30 8 12.5% 0 C1 C2 C3 C4 54% 51% 46% 43% SC IV SC IV Grade 3: 4% Grade 3: 1% ASCO2024, abst #LBA8505, Leighl NB, et al. J Clin Oncol. Published online June 10, 2024:JCO2401001. Grade 3: 4% Grade 3: 4% AE
#32.
Pickup 1 st line @M_Torasawa Ami + Laz 2024/4/8 2nd line G3 AE MARIPOSA Cb + PEM Ami + Laz Cb + PEM + Ami + Laz 3rd line Cb + PEM + Ami Osi PALOMA-3 Cb + PEM Ami (SC) + Laz 25.5mo 6.1mo Ami (SC) + Laz Cb + PEM + Osi PFS ( 63% 92% 34% 58% 72% 18% 56% 52% 13% 13% 6.1mo 4.2mo 18.9mo Osi 35% 6.3mo 18.9mo Ami + Chemo 2024/5/31 75% 8.3mo 18.9mo Osi IRR 4.2mo 23.7mo MARIPOSA-2 AE ) ü Ami (SC)+ Laz Cho BC, et al. LBA14. Ann Oncol. 2023;34:S1306.Passaro A, et al. Ann Oncol. 2024;35(1):77-90. Leighl NB, et al. J Clin Oncol. Published online June 10, 2024:JCO2401001.
#33.
Pickup PALOMA-3 DoR 01 PFS Summary OS C1D1 4 6 Discussion points PK SC C1D2 6 8 7 02 03 IRR ORR VTE 2 VTE MARIPOSA, MARIPOSA-2 ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 @M_Torasawa
#34.
Pickup ニ Uncommon EGFRm NSCLC CHRYSALIS-2 #8516 (Rapid oral abstract) BC. Cho, et al. @M_Torasawa
ROS1およびHER2 NSCLCの最新研究
#35.
Pickup ニ 策 ORR CHRYSALIS-2 I/ Ib @M_Torasawa Cohort A EGFR Ex19 del or L858R Osi Cohort B EGFR Ex20ins SoC Cohort C Uncommon EGFR Cohort D EGFR Ex19 del or L858 Cohort E EGFR Ex19 del or L858R Osi IHC validation Cohort F EGFR Ex19 del or L858R IHC validation R2PD OS CBR PFS ASCO2024, abst #8516, * 3G-EGFRTKI f/u 1/2G EGFR-TKI 規 Osi Osi * validation 1050 mg IV 240 mg 13.8 2 Ami N = 105 ü ü (Afa 47% 53% S768X 32%) G719X L861X G719X L861X S768X E709K E709A L833V R776C R776H R831H V744M V789L V774M Other
#36.
Pickup ニ CHRYSALIS-2 n = 49 n = 56 57% PFS L861X (n = 15) 48% 33% 7.8 + ASCO2024, abst #8516 G719 (n = 33) S768X (n = 12) 48% 19.5 PAPILLON @M_Torasawa Uncommon EGFR Uncommon 50%
#37.
Agenda 5 @M_Torasawa pickup 02 01 EGFR NSCLC EGFR 02 NSCLC ALK ü CROWN Nivo (#LBA8503) vs Pembro ROS1 ü TRUST-1 (#8520) KRAS ü CodeBreak 101 ü KRYSTAL-12 (#8512) (#LBA8509) HER2 ü Beamion-lung1 (#8514) 03 SCLC 04 NSCLC ( / )
#38.
ALK NSCLC @M_Torasawa PFS 9.3 10.9 10.2 11.1 3 (CROWN)1 (ALEX)2 (J-ALEX)3 (ALTA-1L)4 ( ) ( ) ( ) 34.1 34.8 1A 46% 19% ) ( PFS (ALTA-1L) (J-ALEX)3 (ALEX)2 ( ) ( ) (ALEX) 43% 24.1 (ALTA-1L)4 ( 64% ) 2B (ALTA-1L) (CROWN) (CROWN)1 ( 2B 0 6 12 18 24 30 36 ) 5 42 PFS 2023 Pickup #LBA8503 (CROWN) ALK+ NSCLC ASCO 2024 vs. 5 (CROWN) [1] Solomon BJ, et al. Lancet Respir Med. 2023;11(4):354-366.. [2] Mok T, et al. Ann Oncol. 2020;31(8):1056-1064.[3] Nakagawa K, et al. Lung Cancer. 2020;139:195-199 [4] Camidge DR, et al. J Thorac Oncol. 2021;16(12):2091-2108.
#39.
ROS1, HER2 NSCLC ROS-1 @M_Torasawa HER2 1C 1C ASCO 2024 Pickup #8520 (TRUST-1) / ROS1+ NSCLC (abst#8519) Pickup 1C ASCO 2024 Pickup #8514 (Beamion LUNG-1 ) HER2 2023 2023
#40.
KRAS NSCLC @M_Torasawa KRAS ASCO 2024 + CBDCA + PEM Pickup #8512 (CodeBreaK101) KRAS G12C NSCLC + (abst#8510) Pickup + (abst#LBA8511) Pickup 1B ASCO 2024 Pickup 11 #LBA8509 (KRYSTAL-12) NSCLC KRAS G12C vs. / 2023 2023
TRUST-1試験の成果と今後の展望
#41.
Pickup ALK CROWN NSCLC vs. 5 #LBA8503 (Oral abstract) BJ. Solomon, et al. Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. Published online May 31, 2024:JCO2400581. @M_Torasawa
#42.
Pickup CROWN IIIB/IV @M_Torasawa 100mg 1 1 N = 149 ALK+ NSCLC R PS 0 2 わ 1:1 250mg 1 1 N = 147 ü ü 7 PS 2 : L vs C; 2 vs 6% ASCO2024, abst #LBA8503 OS PFS (investigator) ORR 5 ü PFS ü ORR, ORR ü DOR, DOR ü TTP ü ü / PFS 25% PFS (BICR) 50% f/u PD AE PFS 60.2 50% (n = 74) 5% f/u PD AE 55.1 5% (n = 7)
#43.
Pickup CROWN PFS @M_Torasawa PFS 0.19, (95%CI 0.13 0.27) ( ) 100 80 60 48 60% 60 36 24 40 9.1 12 8% 20 0 0 1 2 3 4 5 5 0.06, (95%CI 0.03 0.12) ü 60 ü 16 48 36 24 12 0 ASCO2024, abst #LBA8503 16.4 92% 21% ü ALK variant (1 3), TP53 PFS (TP53mt LOR PFS PFS NR vs 51.6 ) [1] Solomon BJ, et al. Lancet Respir Med. 2023;11(4):354-366.. [2] Mok T, et al. Ann Oncol. 2020;31(8):1056-1064.[3] Nakagawa K, et al. Lung Cancer. 2020;139:195-199 [4] Camidge DR, et al. J Thorac Oncol. 2021;16(12):2091-2108.
#44.
Pickup CROWN @M_Torasawa (n = 31) (N = 29) (n = 31) (n = 90) (n = 87) (n = 89) 100% ALK 48 19 52 33 ALK 3 3 6 12 TP53 48 52 30 26 70 MAPK 0 10 4 4 60 PIK3/MTOR/PTEN 3 10 1 0 50 RTK 3 19 3 6 40 Cell cycle 13 16 4 6 39 45 40 31 16 26 19 32 ctDNA ü ALK ASCO2024, abst #LBA8503. Solomon BJ, et al. J Clin Oncol. Published online May 31, 2024:JCO2400581. 90 80 30 20 10 0
EVOKE-01試験の結果と治療の可能性
#45.
Pickup CROWN @M_Torasawa CNS Grade Grade 3/4 Grade 5 AE Any AE AE AE Grade -100 ü ü ü ü -80 -60 -40 0 20 40 60 80 Grade 1 100 (%) Grade 2 Grade 3 25% 23% Grade 4 21% 12% 0 CNS AE (2 -20 1 ) 3 HLGT HLGT HLGT SMQ ASCO2024, abst #LBA8503. Solomon BJ, et al. J Clin Oncol. Published online May 31, 2024:JCO2400581. 10 NEC 20 30 40 50 (%)
#46.
Pickup AE @M_Torasawa * * * CNS 25mg or 25mg 25mg * ü ü CNS AE Liu G, et al. A pragmatic guide for management of adverse events associated with lorlatinib. Lung Cancer. 2024;191:107535.
#47.
Pickup @M_Torasawa CNS CROWN 25% 37 ; 192 44 ; 63 60.2mo 4.2mo 105 ; 221 34.8mo 5.5mo ALEX 42% L 34.8mo 4.2mo Cb PEM ü 29% B Cb PEM 5.5mo 4.2mo L Cb PEM 59% 2 ü ü 30.8mo 1 CNS 7.1mo 4.2mo 61% ALTA-1L 42% Cb PEM 229 155 ; CNS AE 2 ALK-TKI ALK-TKI
#48.
Pickup CROWN Summary 5 5 01 02 PFS Discussion points 92 % CNS ALK 16 PFS 100mg 03 ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 PFS @M_Torasawa
SCLCにおける新しい治療法の検討
#49.
Pickup / ROS1 ネ NSCLC TRUST-1 #8520 (Rapid Oral abstract) W. Li, et al. Li W, Xiong A, Yang N, et al. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. Published online June 1, 2024:JCO2400731. @M_Torasawa
#50.
Pickup ネ TRUST-1 IIIB/IV @M_Torasawa TKI naïve ROS1+ NSCLC DOR IC-ORR BOR DOR TTR PFS ORR (IRC) 600mg PS 0 1 TKI ROS1 TKI N = 106 TKI ORR N = 67 TKI (%) (%) (%) 56 51 56 61 0: 78% 1 2: 99% 21 34 17 42 91% 600mg ORR G2032R PFS ORR 88% N = 12 TKI 52% 75% 23.5 f/u 9.7 7.6 67% 0 ASCO2024, abst #8520, Li W, et al. J Clin Oncol. Published online June 1, 2024:JCO2400731. f/u 10 20 30 ( )
#51.
Pickup ネ ROS-1 Study TRIDENT-1 [2] [3]* STARTRK-2 [4] [5] PROFILE1001 [6] 106 71 21 53 30 50 91 79 62 68 67 42 19.3 19.2 (88%) IC-ORR (%) ) G2032R ( (23.5 ) ASCO2024 ü (89%) (64%) 35.7 21.0 (59% [10/17]) (0% [0/6]) ) (67% [8/12]) AST * @M_Torasawa TRUST-1 [1] ORR (%) PFS ( TKI (76%) (70%) (21%) 10% ROS1 (62%) (53%) 15% Chol (80%) (36%) (27%) (55%) 19.0 (38%) (44%) #8519 TRK (TrkB) ROS1 CNS [1] Li W, et al. J Clin Oncol. Published online June 1, 2024:JCO2400731. [2] Drilon A, et al. N Engl J Med. 2024;390(2):118-131. [3] Shaw AT, et al. Lancet Oncol. 2019;20(12):1691-1701. [4] Drilon A, et al. Lancet Oncol. 2020;21(2):261-270. [5] Lim SM, et al. J Clin Oncol. 2017;35(23):2613-2618. [6] Shaw AT, et al. N Engl J Med. 2014;371(21):1963-1971.
#52.
Pickup ネ TRUST-1 Summary Discussion points G2032R 01 02 ROS1 TKI AE Phase 3 Phase 2 vs vs TRIDENT 3 NCT06140836 NCT04603807 TRUST-II NCT04919811 ASCO2024, abst #LBA4, Lu Shun, et al. N Engl J Med. 2024. doi:10.1056/NEJMoa2402614 @M_Torasawa
ADRIATIC試験の結果と臨床的意義
#53.
Pick Up HER2 (HER2 TKI: BI 1810631) Beamion LUNG-1 #8514 (Rapid oral abstract) J. Heymach, et al. @M_Torasawa
#54.
Pickup Beamion lung-1 HER2 Rationale I/ TKI HER2 TKI HER2 HER2 / / NSCLC 2 HER2 52% 56% 57% BID 15 30 60 100 150 QD 60 120 180 240 300 MTD 120/240 mg QD ASCO2024, abst #8514 HER2 Phase 1b Phase 1a N = 83 @M_Torasawa 360 HER2 NSCLC 策 1: HER2 TKD 2: HER2 TKD 3: HER2 non-TKD 4: 5: HER2 TKD HER2 TKD HER2 ADC ORR n = 42 TKD Sq
#55.
Pickup Beamion lung-1 Phase1a ORR 74 NSCLC (n = 41) (n = 74) HER2 44% 35% Phase1b ORR T-Dxd HER2 TKD A775_G776insYVMA (n = 32) (n = 12) (n = 34) 38% 36% 62% (n = 16) 69% Phase1b (n = 42) (n = 23) 74% ALT ASCO2024, abst #8514 @M_Torasawa Any G3 67% 10% 29% 21% 10% HER2 HER2 NSCLC T-Dxd 2
#56.
Pickup KRAS G12C 10 NSCLC (CodeBreaK101 ) #8512 (Targeting KRAS in Non Small Cell Lung Cancer) BT. Li, et al. @M_Torasawa
CheckMate77T試験の成果と影響
#57.
Pickup 10 CodeBreaK101 Ib Induction KRAS G12C+ NSCLC PS 0 2 CBDCA PEM @M_Torasawa Maintenance PEM 960 mg 960 mg Until PD 4 TTR PFS OS PK ORR DCR DOR Grade 3 N = 37 N = 21 TRAE (%) ICI 64 67 41 52 (%) (%) ASCO2024, abst #8514 86 16 21 92% 95% ALT AST G3 49% 62% FN -40 -30 -20 -10 0 10 20 30 40 (%)
#58.
Pickup 10 CodeBreaK101 @M_Torasawa CodeBreaK202 PFS ORR DCR f/u 64% 100% 10.8 f/u 42% 84% PD-L1 ASCO2024, abst #8514 PS 0 1 PD-L1 CBDCA+PEM + R + 4 1:1 4.4 + 2 4 6 8 10 12 ( PFS 11.9 KRAS G12C ü ü ü ) ( CBDCA+PEM + PFS ) KEYNOTE-189 PD-L1 NSCLC CodeBreaK202 PEM Until PD 8.3 0 PD-L1 KRAS G12C+ NSCLC 9.2 PFS 6.2 PEM
#59.
Pickup 11 KRAS G12C NSCLC vs. (KRYSTAL-12 ) #LBA8509 (Targeting KRAS in Non Small Cell Lung Cancer) T. Mok, et al. @M_Torasawa
#60.
Pickup 11 IIIB/IV KRYSTAL12 @M_Torasawa KRAS G12C NSCLC R PS 0 1 2:1 /ICI 75 mg/m2 N = 152 / ADA (% Chemo+ICI (%) (%) (chemo/ICI PD ) DOC ADA (%) , ORR (BICR) DoR OS PRO PFS ( BICR) 600mg BID N =301 64 65 64 72 26 26 73 73 17 18 TRAE 94% ADA DOC DOC G1 86% G2 AST G3 ALT G3 47% 46% -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 (%) ASCO2024, abst #8514
NSCLCにおける新しい治療戦略の展望
#61.
Pickup 11 KRYSTAL12 PFS (BICR) 6 0.58, (95%CI 0.45 0.76) p < 0.0001 10 @M_Torasawa CodeBreaK200 PFS ADA DOC 45% 34% 8 6 4 2 5.5 3.8 0 ADA DOC ü ü ü ü ü ü 7.2 ORR (BICR) ADA 32% ORR DOC 9% ADA 24% KRAS G12C PFS ASCO2024, abst #8514, [1] de Langen AJ, et al. Lancet. 2023;401(10378):733-746. ORR DOC 11% NSCLC ORR n = 171 PFS 5.6 ORR 28.1% ORR 33.3% 34% ( Grade) ALT 10% ( Grade) AST 10% ( Grade) n = 174 ü ü ü ü ü [1] PFS 4.5 ORR 13.2% ORR 15.4% 19% ( Grade) 18% ( Grade)
#62.
Agenda @M_Torasawa 2 pickup 03 01 EGFR NSCLC 02 EGFR NSCLC SCLC ü ADRIATIC ü BEAT-SC #LBA5 #8001 04 NSCLC ( / )
#63.
SCLC @M_Torasawa SCLC LD-SCLC ED-SCLC I IIA CASPIAN I IIA + ETP + Durva IMpower133 CBDCA + ETP + Atezo CRT (cCRT > sCRT) CR ASCO 2024 PS SoC PCI Durva CBDCA + ETP + Atezo ± BEV Pickup 13 #8001 BEAT-SC ES-SCLC + ± Durva+Treme ASCO 2024 Pickup 2023 12 #LBA5 ADRIATIC LS-SCLC ± CRT 2023
#64.
Pickup LS-SCLC (ADRIATIC 12 cCRT ) #LBA5 (Plenary) DR. Spigel, et al. @M_Torasawa
ASCO 2024の総括と今後の課題
#65.
Pickup 12 ADRIATIC LS-SCLC (I III PS 0-1 cCRT cCRT PCI @M_Torasawa 1500mg q4w N = 264 ) R D q4w N = 266 1:1:1 SD 24 1500mg+ 75mg (4 1500mg q4w 24, 36 18, 24 ORR TTDM PFS2 ) (I/II vs III), PCI ( Durva CDDP+ETP (%) CRT CR/PR (%) 1 1 (%) PCI (%) ASCO2024, abst #LBA5 Placebo 62 62 66 67 84 88 74 70 54 54 PBO PFS, OS (Dual primary) OS PFS ) Disposition 2 2 34% 46% 26% PD 58% AE 18% ICI PD AE 24.4% ICI
#66.
Pickup 12 ADRIATIC PFS (BICR) 24 @M_Torasawa 18 0.76, (95%CI 0.61 0.95) p = 0.01 49% 20 OS PFS 36% 16 12 8 4 16.6 24 9.2 48 24 34% 12 OS 68% 60 36 55.9 59% OS 33.4 57% 0 27.6 48% 37.2 OS OS PS HR cCRT CRT <65 0 <14 CDDP/ETP 1 1 CR 65 1 14 28 CBDCA/ETP 1 2 PR 28 ASCO2024, abst #LBA5 24 36 PFS 46% 0 0.73, (95%CI 0.57 0.93) p = 0.0104 SD PCI 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
#67.
Pickup 12 ADRIATIC @M_Torasawa G3 24% 24% 23.4 22.9 10.7 38.2 / Grade 32% 10% 5% ASCO2024, abst #LBA5 2% 30.2 G3/4 / 3 3 G5 / 0.4 0 8.8 / -40 Grade 3 6 ü -30 -20 -10 G2 3 0 10 20 30 40 (%)
#68.
Pickup 12 ADRIATIC LS-SCLC OS 01 PFS LS-SCLC ICI LS-SCLC Discussion points cCRT 27% , 2 (OS, ED-SCLC: 2 OS 2 03 ICI cCRT BiTE ASCO2024, abst #LBA5 @M_Torasawa OS ; LS-SCLC: 2 SCLC-I 02 04 Summary ICI DLL-3 2 ICI ICI KEYLYNK-013 NCT04624204 DeLLPhi-306 NCT06117774 [24%] 18% NRG-LU005 NCT03811002 )
#69.
Pickup ES-SCLC + (BEAT-SC 13 ± ) #8001 (Oral abstract) Y. Ohe, et al. @M_Torasawa
#70.
Pickup 13 BEAT-SC @M_Torasawa / PFS ( ES-SCLC PS 0 1 N = 166 R BEV fit OS, ORR, DoR Until PD 1:1 ) / ü ü PS ü PFS 10.2 N = 164 BEV Placebo BEV (%) (%) (%) CBDCA (%) BEV ASCO2024, abst #8001 65 40 13 23 92 7 65 45 12 16 92 G3 AE ü 89% Placebo 90% BEV AE 21% Placebo 17%
#71.
Pickup 13 BEAT-SC PFS (investigator) @M_Torasawa 6 0.70, (95%CI 0.54 0.90) p = 0.006 6 OS PFS BEV 45% 27% 12 1.22, (95%CI 0.89 1.67) p = 0.2212 OS BEV 54% 24 69% 5 4 12 3 5.7 2 1 4.4 0 PFS 12 13.0 20% 11% 28% 0 BEV BEV 48% 264 (160 ) ORR BEV 82% (%) (%) 73% (%) ICI (%) (%) ASCO2024, abst #8001 24 16.0 57 72 26 29 24 22 3 4 10 20 ü OS 34%
#72.
Pickup 13 BEAT-SC PFS Summary + + OS 01 02 Discussion points @M_Torasawa + 0.7 OS OS OS ASCO2024, abst #8001 PFS 1 benefit
#73.
Agenda @M_Torasawa 4 pickup 04 01 EGFR NSCLC 02 EGFR NSCLC 03 SCLC NSCLC ( / ) ü CheckMate816 ü AEGEAN ü CheckMate77T #LBA8010 #8011 #LBA8007 ü EVOKE-01 #LBA8500
#74.
NSCLC @M_Torasawa Neoadjuvant ASCO 2024 C C Optional chemo/RT C 14 #LBA8010 (CheckMate816) NSCLC CheckMate 816 4 N N N CM816 (IB-IIIA) Pickup up to 4 cycles vs Perioperative KN-671 (IIB-IIIA) AEGEAN (IIA-IIIB) CheckMate77T (IIA-IIIB) P P P P C C C C D D D D C C C C N N N N C NEOTORCH (IIA-IIIB) C C C P ( 9 months, Q3W 13 cycles) (abst#8012) Pickup ASCO 2024 S U R G E R Y D ( 12 months, Q4W 12 cycles) N ( 12 months, Q4W 12 cycles) T T T T C C C C T ( 9 months, Q3W 13 cycles) Pickup 15 #8011 (AEGEAN) N2 R-NSCLC AEGEAN ASCO 2024 Pickup 16 #LBA8007 (CheckMate77T) III NSCLC CheckMate77T Adjuvant C IMpower010 (IB-IIIB) up to 4 cycles Optional chemo KN-091 (IIB-IIIB) up to 4 cycles 2023 A ( 12 months, Q3W 16 cycles) P ( 12 months, Q3W 18 cycles) 3 weeks N Nivo T Tori A Atezo P Pembro D Durva C Chemo
#75.
NSCLC Status ICI @M_Torasawa KEYNOTE-671[1] AEGEAN[2] NEOTORCH[3] CheckMate77T[4] CheckMate816[5] 797 740 501 (only Chinese) 461 358 (%) 70.3 68.9 89.6 72.9 71.5 PS 0 (%) 63.7 68.6 34.7 64.2 69.3 Sq (%) 43.1 46.2 77.7 50.7 48.6 (AJCC8th) 29.7 28.4 35.4 - (AJCC 7th) Stage A (AJCC8th) 54.7 47.3 67.3 63.8 - (AJCC 7th) Stage B (AJCC8th) 15.6 24.0 31.9 ICI N Stage EGFR/ALK (ITT ( ) - (AJCC 7th) ) Only CDDP base CDDP < CBDCA base CDDP < CBDCA base CDDP < CBDCA base CDDP > CBDCA base cycle 4 4 3 4 3 cycle (chemo) 0 0 1 0 (optional) cycle (IO) Q3W×13 Q4W×12 Q3W×13 Q4W×12 - EFS, OS (dual) pCR, EFS (mITT) EFS pCR, EFS 25.2 11.7 25.4 57.6 ( ) Perioperative EFS, mPR ( 18.3 ) Neoadjuvant [1] Wakelee Heather, et al. N Engl J Med. 2023;389(6):491-503. [2] Heymach John V., et al. N Engl J Med. 2023;389(18):1672-1684. [3] Lu S, et al. JAMA. 2024;331(3):201-211. [4] Cascone T, et al. N Engl J Med. 2024;390(19):175
#76.
NSCLC @M_Torasawa NSCLC ICI ICI 1A ± 1A 1A S-1 Pickup 17 ASCO 2024 1A TROP2 2023 2023 #LBA8500 (EVOKE-01) NSCLC vs PD(L)-1
#77.
Pickup 14 NSCLC + (CheckMate816 4 vs. ) #LBA8010 (Rapid oral abstract) J Spicer, et al. @M_Torasawa
#78.
Pickup 14 CheckMate816 IB IIIA NSCLC R AJCC 7 PS 0 1 EGFR/ALK ü ü @M_Torasawa + Chemoa N = 179 1:1 (6 pCR (BICR) EFS (BICR Adjuvant (optional) ) MPR (BICR) OS TTDM Chemob ü PD-L1 IB II / IIIA <1 / 1% Nivo a) N = 179 Non-Sq CDDP + PEM or CBDCA + PTX Sq CDDP + GEM or CBDCA + PTX b) CDDP + VNR, CDDP + GEM Disposition IB/ II IIIA Sq PD-L1 < 1% PD-L1 1% CDDP CBDCA 64 36.3 63.1 48.6 43.6 49.7 69.3 21.8 65 34.6 64.2 53.1 43.0 49.7 74.9 18.4 ASCO2024, abst #LBA8010, Forde et al.. N Engl J Med. 2022;386(21):1973-1985. 94% 16% PD 7% AE 1% ( 98% 83% 8% 77%, 17% ( 98% 85% 75% 21% PD 10% AE 1% 10% 61%, 25%
#79.
Pickup 14 EFS 57.6 48 42 36 30 24 18 12 6 0 CheckMate816 @M_Torasawa 36 0.66, (95%CI 0.49 0.90) P = 0.0451 EFS OS Nivo 53% *OS 40% p = 0.0164 0.671 (95%CI 0.47 1.07) P = 0.0451* 57.6 77% 60 43.8 36 EFS 48 24 18.4 49% 12 38% Nivo Nivo OS (%) (%) Chemo (%) VEGF EGFR/ALK TKI EGFR/ALK ASCO2024, abst #LBA8010 53 23 7 40 21 15 3 71 35 7 39 42 15 10 CDDP HR 0.79 CBDCA HR 0.36 40 60 95% 80 ( 58% 48 OS Non-pCR pCR NC 20 OS Nivo HR 0.71 0 64% 71% 0 Nivo OS Nivo 48 48 36 ) 63%
#80.
Pickup 14 CheckMate816 @M_Torasawa ctDNA 86 (24%) ü AE Nivo 56% vs OS HR 0.31 (0.10-0.64) 24/43 35% Nivo ctDNA 36 48 6 5 7 AE SAE vs -100 11 -80 -60 -40 -20 15/43 pCR ctDNA ASCO2024, abst #LBA8010 3 84 8 AE OS HR 0.58 (0.20 1.64) 38 52 EFS OS 34 34 0 2 0 15 G1 2 G3 4 20 40 60 80 100 (%)
#81.
Pickup N2 15 NSCLC AEGEAN #8011 (Rapid oral abstract) J Heymach, et al. @M_Torasawa
#82.
Pickup 15 AEGEAN IIA IIIB[N2] @M_Torasawa NSCLC R AJCC 8 PS 0 1 EGFR/ALK ü ü PD-L1 + Chemo N = 181 pCR (BICR) EFS (BICR 1:1 II / III <1 / 49.5% 366/740 N2 ASCO2024, abst #8011 1 ) MPR (BICR) DFS + Chemo N = 185 1% Durva N2 N2 (40 (n =181) 100 (n =185) Disposition 80 IIIA IIIB Sq N2 single N2 multi PD-L1 < 1% CBDCA 62 51.9 48.1 45.9 77.9 18.8 32.6 70.2 65 46.5 53.0 55.1 71.4 21.6 33.5 73.5 (%) 60 40 20 0 Durva D-N2 ü N2 ITT D-ITT R0 PBO-N2 PBO-ITT disposition
#83.
Pickup 15 AEGEAN @M_Torasawa pCR, mPR 100 40 80 (%) 17.5% 30 60 (%) 40 20 11.7% 13.0% 20 10 0 0 D-N2 D-ITT PBO-N2 PBO-ITT ü N2 D-N2 ü N2 EFS ITT HR 0.68 (0.53 0.88) 25.9 mf/u 11.7 N2 HR 0.63 (0.43 0.9) 19.5 mf/u 11.8 0 pCR 6 ASCO2024, abst #8011 12 18 24 30 36 ( ) MPR ü N2 N2 MPR D-ITT PBO-N2 PBO-ITT pCR MPR rate ITT G3 / 4 NSCLC 21%
#84.
Pickup 16 III NSCLC (CheckMate77T ) #8070 (Oral abstract) MP Pulla, et al. @M_Torasawa
#85.
Pickup 16 CheckMate77T IIA (>4cm) IIIB[N2] NSCLC III Nivo IIIA IIIB PS 0 Sq PD-L1 < 1% PD-L1 1 49 % PD-L1 50% ASCO2024, abst #LBA8007 + 1:1 II / III ü PD-L1 (Sq / non-Sq) N2 Chemo N = 181 R AJCC 8 PS 0 1 EGFR/ALK ü ü @M_Torasawa 66 53 47 74 44 45 40 13 <1 / EFS (BICR (6 ) Nivo (n =55) 13 + Chemo N = 185 1% pCR (BICR) MPR (BICR) OS 360 mg Q3W (n =91) (n =90) 64 63 37 66 42 39 32 24 III non-N2 IIIA IIIB PS 0 Sq PD-L1 < 1% PD-L1 1 49 % PD-L1 50% 66 100 0 56 56 44 27 27 (n =57) 65 100 0 58 60 49 30 19 ü non-N2 N2 N2 PS0 non-Sq
#86.
Pickup 16 CheckMate77T @M_Torasawa pCR 40 37.5% 24.4% 21% EFS 20 EFS) HR 0.32 (0.19 0.54) III non-N2 HR 0.61 (0.30 1.24) HR 0.40 (0.20 0.78) HR 0.23 (0.09 0.58) III single-N2 10 III multi-N2 0 (%) ( III N2 13.6% 30 mf/u25.4 III N2 III non-N2 III single-station N2 III 0 multi- station N2 ü N2 Nivo ypN0 ypN0 ASCO2024, abst #LBA8007 36% 57% 12 18 24 Nivo 30 benefit III Nivo Nivo 46% N2 6 N2 Nivo 44% 1% 14% 36 ( )
#87.
Pickup 16 / N0 T1–2 @M_Torasawa N2 single Discrete/non-bulky N2 multi Discrete/non-bulky N2 Bulky (N2a/b) N2 Invasive (N2a/b) N3 切除可能 切除可能な 可能性あり 不明 切除不能 切除不能 切除可能 切除可能 切除可能な 可能性あり 切除不能 切除不能 切除不能 N1 III T3 T4 切除可能 切除可能 切除可能 切除可能な 可能性あり 切除不能 切除不能 切除不能 T4 invasion* 切除可能な 可能性あり 切除可能な 可能性あり 切除可能な 可能性あり 切除可能な 可能性あり 切除不能 切除不能 切除不能 p PACIFIC p ICI (neoadjuvant +/- adjuvant ICI) WCLC 2023 abst# OA06.05
#88.
Pickup 16 CheckMate77T Summary N2 N2 01 02 03 Discussion points III @M_Torasawa NSCLC ypN0 ICI N2 non-N2 . Nivo N2 EFS N2 non-N2 N2-multi NCCN, ESMO N2 single-station N2 pCR 策 ASCO2024, abst #LBA8007 EFS pCR Nivo EFS
#89.
Pickup 17 PD(L)-1 NSCLC vs (EVOKE-01 ) #LBA8500 (Oral abstract) Paz-Ales LG, et al. Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Published online May 31, 2024:JCO2400733. @M_Torasawa
#90.
Pickup 17 EVOKE-01 @M_Torasawa Stage IV NSCLC PS 0 1 Actionable 1 Topo1 N = 299 R ICI PFS, ORR, DoR, DCR (investigator) 1:1 N = 304 TROP2 ü ü ü 66 55.9 34.4 9.7 11.7 QOL : (Sq / Non-sq) ICI (CR/PR, PD/SD) 64 54.9 33.2 11.8 12.8 Non-Sq (%) ICI; CR+PR (%) ICI; SD+PD (%) EGFR-TKI (%) ALK-TKI (%) 71.9 35.5 64.2 2.0 0.3 ASCO2024, abst #LBA8500, Paz-Ares LG, et al. J Clin Oncol. Published online May 31, 2024:JCO2400733. p α 0.0223 Disposition SG SG 1 (%) 2 (%) 3 (%) (%) OS SG 73.7 37.2 62.8 4.3 0.3 (n =296*) 12.8% 67.9% * (n = 288*) 4.9% 60.4%
#91.
Pickup 17 OS 12.7 EVOKE-01 @M_Torasawa PFS 0.84, (95%CI 0.68 1.04) P = 0.0534 12 SG EFS 12.7 DOC 12 47% 8 6 2 SG 10 37% 14% 8 6 11.1 9.8 4.1 4 2 0 18% 3.9 0 SG SG OS OS HR PS <65 65 *PD/SD DOC 12 10 4 ORR 0.92, (95%CI 0.77 1.11) ICI Sq 0 PD/SD* Non-Sq 1 CR/PR HR 0.75 (95%CI: 0.58 0.97) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 ASCO2024, abst #LBA8500, Paz-Ares LG, et al. J Clin Oncol. Published online May 31, 2024:JCO2400733. ICI SD/PD Nonresponsive (non-responsive) HR 0.75 Responsive CR/PR HR 1.09 Non-Sq (non-responsive) HR 0.79 Sq (non-responsive) HR 0.62 ICI 0 2 4 6 8 10 12
#92.
Pickup 17 G3 AE EVOKE-01 @M_Torasawa DOC SG SG DOC 67% 76% 17% 10% AE SG Overall DOC 33 44 40 -60 1 1 2 1 34 6 6 13 25 37 -40 -20 0 G3 ü 46 30 10 4 43 -80 22 13 10 42 -100 76 67 29 ü 25 G1 2 25 G3 6 20 40 60 80 ASCO2024, abst #LBA8500, Paz-Ares LG, et al. J Clin Oncol. Published online May 31, 2024:JCO2400733. 100 ü AE SG SG
#93.
Pickup 17 TROPION-Lung01 EVOKE-01 Status TROPION-Lung01[1] EVOKE-01[2] N 299 299 TROP2 ADC @M_Torasawa HR 0.92 PFS Deruxtecan derivaive SN-38 4 7.6 6mg/kg day1 q3w 10mg/kg day1/8 q3w 61 65 Non-Sq(%) 76 72 (%) 17 DAR (%) 1(%) 56 12 56 2(%) 36 34 7 10 99 100 88 100 15 6 PFS, OS OS 3(%) (%) ICI (%) (%) Primary Endpoint [1] ESMO 2023 #LBA12. [2] ASCO2024, abst #LBA8500. SG DOC (EVOKE-01) Dato-Dxd DOC (TROPION-Lung01) HR 0.75 HR 0.84 OS HR 0.90* 0 *74% 2 4 6 8 10 12 OS 2024.5.27 ü 2 PFS, OS DOC 14 ( )
#94.